NCT00594308 · ADVERSE EVENTS

Adverse events

In-Vivo Activated T-Cell Depletion to Prevent GVHD · Source last updated 2014-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Basiliximab 20 mg All patients that received Basiliximab 20 mg monoclonal therapy	4 / 10	0 / 10	Not reported / Not reported

Group identifiers: EG000: Basiliximab 20 mg

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
GvHD
stats
group Id
EG000
num Affected
4
num At Risk
10
num Events
4
term
GvHD

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
All patients that received Basiliximab 20 mg monoclonal therapy
id
EG000
other Num Affected
0
other Num At Risk
10
serious Num Affected
4
serious Num At Risk
10
title
Basiliximab 20 mg

frequency Threshold

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
GvHD
stats
group Id
EG000
num Affected
4
num At Risk
10
num Events
4
term
GvHD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice